Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial
Background The sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure. Experimental studies suggest a direct cardiac effect of empagliflozin associated with an improvement in left ventricular diastoli...
Saved in:
| Published in | Clinical research in cardiology Vol. 112; no. 7; pp. 911 - 922 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.07.2023
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1861-0684 1861-0692 1861-0692 |
| DOI | 10.1007/s00392-023-02164-w |
Cover
| Abstract | Background
The sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure. Experimental studies suggest a direct cardiac effect of empagliflozin associated with an improvement in left ventricular diastolic function.
Methods
In the randomized, double-blind, two-armed, placebo-controlled, parallel group trial EmDia, patients with T2DM and elevated left ventricular
E
/
E
´ ratio were enrolled and randomized 1:1 to receive empagliflozin 10 mg/day versus placebo. The primary endpoint was the change of left ventricular
E
/
E
´ ratio after 12 weeks of intervention.
Results
A total of 144 patients with T2DM and an elevated left ventricular
E
/
e
´ ratio (age 68.9 ± 7.7 years; 14.1% women;
E
/
e
´ ratio 9.61[8.24/11.14], left ventricular ejection fraction 58.9% ± 5.6%). After 12 weeks of intervention, empagliflozin resulted in a significant higher decrease in the primary endpoint
E
/
e
´ ratio by − 1.18 ([95% confidence interval (CI) − 1.72/− 0.65];
P
< 0.0001) compared with placebo. The beneficial effect of empagliflozin was consistent across all subgroups and also occurred in subjects with heart failure and preserved ejection fraction (
n
= 30). Additional effects of empagliflozin on body weight, HbA1c, uric acid, red blood cell count, hemoglobin, mean corpuscular hemoglobin, and hematocrit were detected (all
P
< 0.001). Approximately one-third of the reduction in
E
/
e
´ by empagliflozin could be explained by the variables examined.
Conclusions
Empagliflozin improves diastolic function in patients with T2DM and elevated end-diastolic pressure. Since the positive effects were consistent in patients with and without heart failure with preserved ejection fraction, the data add a mechanistic insight for the beneficial cardiovascular effect of empagliflozin.
Trial registration
Clinicaltrials.gov, unique identifier: NCT02932436.
Graphical abstract |
|---|---|
| AbstractList | BackgroundThe sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure. Experimental studies suggest a direct cardiac effect of empagliflozin associated with an improvement in left ventricular diastolic function.MethodsIn the randomized, double-blind, two-armed, placebo-controlled, parallel group trial EmDia, patients with T2DM and elevated left ventricular E/E´ ratio were enrolled and randomized 1:1 to receive empagliflozin 10 mg/day versus placebo. The primary endpoint was the change of left ventricular E/E´ ratio after 12 weeks of intervention.ResultsA total of 144 patients with T2DM and an elevated left ventricular E/e´ ratio (age 68.9 ± 7.7 years; 14.1% women; E/e´ ratio 9.61[8.24/11.14], left ventricular ejection fraction 58.9% ± 5.6%). After 12 weeks of intervention, empagliflozin resulted in a significant higher decrease in the primary endpoint E/e´ ratio by − 1.18 ([95% confidence interval (CI) − 1.72/− 0.65]; P < 0.0001) compared with placebo. The beneficial effect of empagliflozin was consistent across all subgroups and also occurred in subjects with heart failure and preserved ejection fraction (n = 30). Additional effects of empagliflozin on body weight, HbA1c, uric acid, red blood cell count, hemoglobin, mean corpuscular hemoglobin, and hematocrit were detected (all P < 0.001). Approximately one-third of the reduction in E/e´ by empagliflozin could be explained by the variables examined.ConclusionsEmpagliflozin improves diastolic function in patients with T2DM and elevated end-diastolic pressure. Since the positive effects were consistent in patients with and without heart failure with preserved ejection fraction, the data add a mechanistic insight for the beneficial cardiovascular effect of empagliflozin.Trial registrationClinicaltrials.gov, unique identifier: NCT02932436. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure. Experimental studies suggest a direct cardiac effect of empagliflozin associated with an improvement in left ventricular diastolic function.BACKGROUNDThe sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure. Experimental studies suggest a direct cardiac effect of empagliflozin associated with an improvement in left ventricular diastolic function.In the randomized, double-blind, two-armed, placebo-controlled, parallel group trial EmDia, patients with T2DM and elevated left ventricular E/E´ ratio were enrolled and randomized 1:1 to receive empagliflozin 10 mg/day versus placebo. The primary endpoint was the change of left ventricular E/E´ ratio after 12 weeks of intervention.METHODSIn the randomized, double-blind, two-armed, placebo-controlled, parallel group trial EmDia, patients with T2DM and elevated left ventricular E/E´ ratio were enrolled and randomized 1:1 to receive empagliflozin 10 mg/day versus placebo. The primary endpoint was the change of left ventricular E/E´ ratio after 12 weeks of intervention.A total of 144 patients with T2DM and an elevated left ventricular E/e´ ratio (age 68.9 ± 7.7 years; 14.1% women; E/e´ ratio 9.61[8.24/11.14], left ventricular ejection fraction 58.9% ± 5.6%). After 12 weeks of intervention, empagliflozin resulted in a significant higher decrease in the primary endpoint E/e´ ratio by - 1.18 ([95% confidence interval (CI) - 1.72/- 0.65]; P < 0.0001) compared with placebo. The beneficial effect of empagliflozin was consistent across all subgroups and also occurred in subjects with heart failure and preserved ejection fraction (n = 30). Additional effects of empagliflozin on body weight, HbA1c, uric acid, red blood cell count, hemoglobin, mean corpuscular hemoglobin, and hematocrit were detected (all P < 0.001). Approximately one-third of the reduction in E/e´ by empagliflozin could be explained by the variables examined.RESULTSA total of 144 patients with T2DM and an elevated left ventricular E/e´ ratio (age 68.9 ± 7.7 years; 14.1% women; E/e´ ratio 9.61[8.24/11.14], left ventricular ejection fraction 58.9% ± 5.6%). After 12 weeks of intervention, empagliflozin resulted in a significant higher decrease in the primary endpoint E/e´ ratio by - 1.18 ([95% confidence interval (CI) - 1.72/- 0.65]; P < 0.0001) compared with placebo. The beneficial effect of empagliflozin was consistent across all subgroups and also occurred in subjects with heart failure and preserved ejection fraction (n = 30). Additional effects of empagliflozin on body weight, HbA1c, uric acid, red blood cell count, hemoglobin, mean corpuscular hemoglobin, and hematocrit were detected (all P < 0.001). Approximately one-third of the reduction in E/e´ by empagliflozin could be explained by the variables examined.Empagliflozin improves diastolic function in patients with T2DM and elevated end-diastolic pressure. Since the positive effects were consistent in patients with and without heart failure with preserved ejection fraction, the data add a mechanistic insight for the beneficial cardiovascular effect of empagliflozin.CONCLUSIONSEmpagliflozin improves diastolic function in patients with T2DM and elevated end-diastolic pressure. Since the positive effects were consistent in patients with and without heart failure with preserved ejection fraction, the data add a mechanistic insight for the beneficial cardiovascular effect of empagliflozin.Clinicaltrials.gov, unique identifier: NCT02932436.TRIAL REGISTRATIONClinicaltrials.gov, unique identifier: NCT02932436. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure. Experimental studies suggest a direct cardiac effect of empagliflozin associated with an improvement in left ventricular diastolic function. In the randomized, double-blind, two-armed, placebo-controlled, parallel group trial EmDia, patients with T2DM and elevated left ventricular E/E´ ratio were enrolled and randomized 1:1 to receive empagliflozin 10 mg/day versus placebo. The primary endpoint was the change of left ventricular E/E´ ratio after 12 weeks of intervention. A total of 144 patients with T2DM and an elevated left ventricular E/e´ ratio (age 68.9 ± 7.7 years; 14.1% women; E/e´ ratio 9.61[8.24/11.14], left ventricular ejection fraction 58.9% ± 5.6%). After 12 weeks of intervention, empagliflozin resulted in a significant higher decrease in the primary endpoint E/e´ ratio by - 1.18 ([95% confidence interval (CI) - 1.72/- 0.65]; P < 0.0001) compared with placebo. The beneficial effect of empagliflozin was consistent across all subgroups and also occurred in subjects with heart failure and preserved ejection fraction (n = 30). Additional effects of empagliflozin on body weight, HbA1c, uric acid, red blood cell count, hemoglobin, mean corpuscular hemoglobin, and hematocrit were detected (all P < 0.001). Approximately one-third of the reduction in E/e´ by empagliflozin could be explained by the variables examined. Empagliflozin improves diastolic function in patients with T2DM and elevated end-diastolic pressure. Since the positive effects were consistent in patients with and without heart failure with preserved ejection fraction, the data add a mechanistic insight for the beneficial cardiovascular effect of empagliflozin. Clinicaltrials.gov, unique identifier: NCT02932436. Background The sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure. Experimental studies suggest a direct cardiac effect of empagliflozin associated with an improvement in left ventricular diastolic function. Methods In the randomized, double-blind, two-armed, placebo-controlled, parallel group trial EmDia, patients with T2DM and elevated left ventricular E / E ´ ratio were enrolled and randomized 1:1 to receive empagliflozin 10 mg/day versus placebo. The primary endpoint was the change of left ventricular E / E ´ ratio after 12 weeks of intervention. Results A total of 144 patients with T2DM and an elevated left ventricular E / e ´ ratio (age 68.9 ± 7.7 years; 14.1% women; E / e ´ ratio 9.61[8.24/11.14], left ventricular ejection fraction 58.9% ± 5.6%). After 12 weeks of intervention, empagliflozin resulted in a significant higher decrease in the primary endpoint E / e ´ ratio by − 1.18 ([95% confidence interval (CI) − 1.72/− 0.65]; P < 0.0001) compared with placebo. The beneficial effect of empagliflozin was consistent across all subgroups and also occurred in subjects with heart failure and preserved ejection fraction ( n = 30). Additional effects of empagliflozin on body weight, HbA1c, uric acid, red blood cell count, hemoglobin, mean corpuscular hemoglobin, and hematocrit were detected (all P < 0.001). Approximately one-third of the reduction in E / e ´ by empagliflozin could be explained by the variables examined. Conclusions Empagliflozin improves diastolic function in patients with T2DM and elevated end-diastolic pressure. Since the positive effects were consistent in patients with and without heart failure with preserved ejection fraction, the data add a mechanistic insight for the beneficial cardiovascular effect of empagliflozin. Trial registration Clinicaltrials.gov, unique identifier: NCT02932436. Graphical abstract |
| Author | Münzel, Thomas Koeck, Thomas Shah, Sanjiv J. Schulz, Andreas Baumkötter, Rieke Gori, Tommaso Zahn, Daniela Daiber, Andreas Jünger, Claus Tröbs, Sven-Oliver Binder, Harald Arnold, Natalie Lackner, Karl J. Müller, Felix Heidorn, Marc William Wild, Philipp S. Prochaska, Jürgen H. |
| Author_xml | – sequence: 1 givenname: Jürgen H. surname: Prochaska fullname: Prochaska, Jürgen H. organization: Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg-University Mainz, German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main – sequence: 2 givenname: Claus surname: Jünger fullname: Jünger, Claus organization: Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg-University Mainz – sequence: 3 givenname: Andreas surname: Schulz fullname: Schulz, Andreas organization: Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz – sequence: 4 givenname: Natalie surname: Arnold fullname: Arnold, Natalie organization: Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Department of Cardiology, University Heart and Vascular Center Hamburg – sequence: 5 givenname: Felix surname: Müller fullname: Müller, Felix organization: Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main – sequence: 6 givenname: Marc William surname: Heidorn fullname: Heidorn, Marc William organization: Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main – sequence: 7 givenname: Rieke surname: Baumkötter fullname: Baumkötter, Rieke organization: Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz – sequence: 8 givenname: Daniela surname: Zahn fullname: Zahn, Daniela organization: Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz – sequence: 9 givenname: Thomas surname: Koeck fullname: Koeck, Thomas organization: Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz – sequence: 10 givenname: Sven-Oliver surname: Tröbs fullname: Tröbs, Sven-Oliver organization: Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main – sequence: 11 givenname: Karl J. surname: Lackner fullname: Lackner, Karl J. organization: German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg-University Mainz – sequence: 12 givenname: Andreas surname: Daiber fullname: Daiber, Andreas organization: German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz – sequence: 13 givenname: Harald surname: Binder fullname: Binder, Harald organization: Institute of Medical Biometry and Statistics, University of Freiburg – sequence: 14 givenname: Sanjiv J. surname: Shah fullname: Shah, Sanjiv J. organization: Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine – sequence: 15 givenname: Tommaso surname: Gori fullname: Gori, Tommaso organization: German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz – sequence: 16 givenname: Thomas surname: Münzel fullname: Münzel, Thomas organization: German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz – sequence: 17 givenname: Philipp S. orcidid: 0000-0003-4413-9752 surname: Wild fullname: Wild, Philipp S. email: philipp.wild@unimedizin-mainz.de organization: Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg-University Mainz, German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, Systems Medicine, Institute for Molecular Biology (IMB) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36763159$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UkluFDEULaEgMsAFWCBLbFikwEO5qrxCUWgGKRIbWFsu16-OI5fdeOhWsuIQnIwjcBLc6dBAFllYtvzfe__94bg6cN5BVT0n-DXBuHsTMWaC1piyckjb1JtH1RHpW1LjVtCD_btvDqvjGK8w5gSz5kl1yNquZYSLo-rnYppAp4j8hGBeqaU1k_U3xiHvkIUpoTW4FIzOVgU0GhWTt0ajKTudTMEUpBpHc_tOHuWYlUVaBdhGjBvN2ozlK6KNSZcoXa8A0a3OAAkimsFak3L89f1HgJhtMTIFP6N0CSgoN_rZ3MB4ikafBwv1YIviKVpZpWHwtfbFmrcWRrSY3xmFilFln1aPp5IQnt3dJ9XX94sv5x_ri88fPp2fXdS66XiqWzpyLhQfQE1C074fNBZ8EH3Tl4JY00CvOsahpW0JAcENCMo5mZpWc6oYO6ne7nRXeZhh1Ns-KStXwcwqXEuvjPw_4sylXPq1JJgK1vC2KLy6Uwj-W4aY5GyiLi1RDnyOknYdbykTDSnQl_egVz4HV-qTtKeCd2XioqBe_Gtp7-XPvAuA7gA6-BgDTHsIwXK7VHK3VLIslbxdKrkppP4eSZukthMvZRn7MJXtqLHkcUsIf20_wPoN5cnoTg |
| CitedBy_id | crossref_primary_10_2147_DMSO_S422327 crossref_primary_10_1186_s12933_024_02344_6 crossref_primary_10_18087_cardio_2024_7_n2545 crossref_primary_10_1007_s00392_024_02386_6 crossref_primary_10_1007_s10557_024_07576_y crossref_primary_10_15420_cfr_2023_25 crossref_primary_10_1016_j_ejim_2024_08_012 crossref_primary_10_1007_s00392_024_02424_3 |
| Cites_doi | 10.1093/eurheartj/ehv728 10.1056/NEJMoa1313731 10.1007/s00125-018-4670-7 10.1056/NEJMoa1911303 10.1001/jama.2013.905 10.1007/s10741-018-9668-1 10.1161/CIRCULATIONAHA.120.052503 10.1161/CIRCULATIONAHA.120.045691 10.2459/JCM.0000000000001267 10.1093/cvr/cvaa123 10.1016/j.jchf.2019.04.024 10.1093/eurheartj/ehz486 10.1056/NEJMoa1504720 10.1016/j.echo.2014.10.003 10.1093/eurheartj/ehaa419 10.1001/jamacardio.2020.6827 10.1161/CIRCULATIONAHA.119.044235 10.1056/NEJMoa2022190 10.1186/s12933-020-01209-y 10.1016/j.jacc.2020.11.008 10.1002/ejhf.1328 10.7326/0003-4819-150-9-200905050-00006 10.1161/JAHA.119.015103 10.1161/CIRCULATIONAHA.120.051992 10.1002/dmrr.3335 10.1001/jamacardio.2020.7184 10.1056/NEJMoa2107038 10.1007/s00592-021-01823-6 10.1093/eurheartj/ehq473 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FR3 FYUFA GHDGH K9. M0S M1P M7Z P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s00392-023-02164-w |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection (NC LIVE) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Biochemistry Abstracts 1 Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Biochemistry Abstracts 1 Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Technology Research Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1861-0692 |
| EndPage | 922 |
| ExternalDocumentID | PMC10293456 36763159 10_1007_s00392_023_02164_w |
| Genre | Randomized Controlled Trial Journal Article |
| GrantInformation_xml | – fundername: Deutsches Zentrum für Herz-Kreislaufforschung funderid: http://dx.doi.org/10.13039/100010447 – fundername: Bundesministerium für Bildung und Forschung grantid: BMBF 01EO1503; BMBF 161L0217A funderid: http://dx.doi.org/10.13039/501100002347 – fundername: Universitätsmedizin der Johannes Gutenberg-Universität Mainz (8974) – fundername: Boehringer Ingelheim funderid: http://dx.doi.org/10.13039/100008349 – fundername: Bundesministerium für Bildung und Forschung grantid: BMBF 01EO1503 – fundername: Bundesministerium für Bildung und Forschung grantid: BMBF 161L0217A – fundername: ; – fundername: ; grantid: BMBF 01EO1503; BMBF 161L0217A |
| GroupedDBID | --- -5E -5G -BR -EM -Y2 -~C .VR 06C 06D 0R~ 0VY 1N0 203 29B 29~ 2J2 2JN 2JY 2KG 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5VS 67Z 6NX 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSNA ACZOJ ADBBV ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LLZTM M1P M4Y MA- N2Q N9A NB0 NPVJJ NQJWS NU0 O9- O93 O9I O9J OAM P9S PF0 PQQKQ PROAC PSQYO PT4 Q2X QOR QOS R89 R9I ROL RSV S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z81 Z82 Z83 Z87 ZMTXR ZOVNA ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY 7XB 8FD 8FK FR3 K9. M7Z P64 PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c475t-62d559a5beaf9c288bc095b9848add344e8a735e6268bce104e92551f46c52a33 |
| IEDL.DBID | AGYKE |
| ISSN | 1861-0684 1861-0692 |
| IngestDate | Thu Aug 21 18:37:06 EDT 2025 Fri Sep 05 08:06:19 EDT 2025 Fri Jul 25 19:54:21 EDT 2025 Mon Jul 21 05:54:48 EDT 2025 Tue Jul 01 03:31:09 EDT 2025 Thu Apr 24 23:08:53 EDT 2025 Fri Feb 21 02:43:14 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Heart failure Diastolic function Biomarkers Clinical trial Type 2 diabetes mellitus |
| Language | English |
| License | 2023. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c475t-62d559a5beaf9c288bc095b9848add344e8a735e6268bce104e92551f46c52a33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| ORCID | 0000-0003-4413-9752 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/s00392-023-02164-w |
| PMID | 36763159 |
| PQID | 2829576929 |
| PQPubID | 326353 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10293456 proquest_miscellaneous_2775623941 proquest_journals_2829576929 pubmed_primary_36763159 crossref_primary_10_1007_s00392_023_02164_w crossref_citationtrail_10_1007_s00392_023_02164_w springer_journals_10_1007_s00392_023_02164_w |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-07-01 |
| PublicationDateYYYYMMDD | 2023-07-01 |
| PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Clinical research in cardiology |
| PublicationTitleAbbrev | Clin Res Cardiol |
| PublicationTitleAlternate | Clin Res Cardiol |
| PublicationYear | 2023 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Pabel, Wagner, Bollenberg, Bengel, Kovács, Schach (CR7) 2018; 20 Griffin, Rao, Ivey-Miranda, Fleming, Mahoney, Maulion (CR26) 2020; 142 Shim, Seo, Cho, Lee, Cho, Lhagvasuren (CR14) 2021; 143 Filippatos, Ahmed, Gladden, Mujib, Aban, Love (CR28) 2011; 32 Rai, Connelly, Verma, Mazer, Teoh, Ng (CR21) 2022; 59 McMurray, Solomon, Inzucchi, Køber, Kosiborod, Martinez (CR13) 2019; 381 Zinman, Wanner, Lachin, Fitchett, Bluhmki, Hantel (CR2) 2015; 373 Jünger, Prochaska, Gori, Schulz, Binder, Daiber (CR9) 2022; 23 Pitt, Pfeffer, Assmann, Boineau, Anand, Claggett (CR24) 2014; 370 Yu, Zhao, Wang, Zhou, Huang, Zhai (CR12) 2021; 20 Kolijn, Pabel, Tian, Lódi, Herwig, Carrizzo (CR8) 2021; 117 Fitchett, Zinman, Wanner, Lachin, Hantel, Salsali (CR3) 2016; 37 Cosentino, Grant, Aboyans, Bailey, Ceriello, Delgado (CR1) 2020; 41 Tröbs, Prochaska, Schwuchow-Thonke, Schulz, Müller, Heidorn (CR29) 2021; 6 Packer, Anker, Butler, Filippatos, Pocock, Carson (CR4) 2020; 383 CR5 Levey, Stevens, Schmid, Zhang, Castro, Feldman (CR10) 2009; 150 Tanaka, Hirata (CR16) 2018; 23 Nassif, Qintar, Windsor, Jermyn, Shavelle, Tang (CR22) 2021; 143 Santos-Gallego, Vargas-Delgado, Requena-Ibanez, Garcia-Ropero, Mancini, Pinney (CR20) 2021; 77 Carbone, Billingsley, Canada, Bressi, Rotelli, Kadariya (CR18) 2020; 36 Omar, Jensen, Ali, Frederiksen, Kistorp, Videbæk (CR19) 2021; 6 Mazer, Hare, Connelly, Gilbert, Shehata, Quan (CR27) 2020; 141 Anker, Butler, Filippatos, Ferreira, Bocchi, Böhm (CR25) 2021; 385 Lang, Badano, Mor-Avi, Afilalo, Armstrong, Ernande (CR11) 2015; 28 Ejiri, Miyoshi, Kihara, Hata, Nagano, Takaishi (CR17) 2020; 9 Verma, McMurray (CR6) 2018; 61 Brown, Gandy, McCrimmon, Houston, Struthers, Lang (CR15) 2020; 41 Edelmann, Wachter, Schmidt, Kraigher-Krainer, Colantonio, Kamke (CR23) 2013; 309 Benfari, Miller, Antoine, Rossi, Lin, Oh (CR30) 2019; 7 Fitchett, Zinman, Wanner, Lachin, Hantel, Salsali (CR31) 2016; 37 M Omar (2164_CR19) 2021; 6 G Benfari (2164_CR30) 2019; 7 S Verma (2164_CR6) 2018; 61 B Pitt (2164_CR24) 2014; 370 GS Filippatos (2164_CR28) 2011; 32 A Rai (2164_CR21) 2022; 59 CD Mazer (2164_CR27) 2020; 141 D Fitchett (2164_CR3) 2016; 37 C Jünger (2164_CR9) 2022; 23 CY Shim (2164_CR14) 2021; 143 JJV McMurray (2164_CR13) 2019; 381 2164_CR5 K Ejiri (2164_CR17) 2020; 9 M Griffin (2164_CR26) 2020; 142 M Packer (2164_CR4) 2020; 383 F Edelmann (2164_CR23) 2013; 309 YW Yu (2164_CR12) 2021; 20 SD Anker (2164_CR25) 2021; 385 SO Tröbs (2164_CR29) 2021; 6 H Tanaka (2164_CR16) 2018; 23 F Cosentino (2164_CR1) 2020; 41 D Kolijn (2164_CR8) 2021; 117 CG Santos-Gallego (2164_CR20) 2021; 77 ME Nassif (2164_CR22) 2021; 143 RM Lang (2164_CR11) 2015; 28 D Fitchett (2164_CR31) 2016; 37 AS Levey (2164_CR10) 2009; 150 AJM Brown (2164_CR15) 2020; 41 S Pabel (2164_CR7) 2018; 20 S Carbone (2164_CR18) 2020; 36 B Zinman (2164_CR2) 2015; 373 |
| References_xml | – volume: 37 start-page: 1526 issue: 19 year: 2016 end-page: 1534 ident: CR31 article-title: Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv728 – volume: 370 start-page: 1383 issue: 15 year: 2014 end-page: 1392 ident: CR24 article-title: Spironolactone for heart failure with preserved ejection fraction publication-title: N Engl J Med doi: 10.1056/NEJMoa1313731 – volume: 61 start-page: 2108 issue: 10 year: 2018 end-page: 2117 ident: CR6 article-title: SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review publication-title: Diabetologia doi: 10.1007/s00125-018-4670-7 – volume: 381 start-page: 1995 issue: 21 year: 2019 end-page: 2008 ident: CR13 article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction publication-title: N Engl J Med doi: 10.1056/NEJMoa1911303 – volume: 309 start-page: 781 issue: 8 year: 2013 end-page: 791 ident: CR23 article-title: Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial publication-title: JAMA doi: 10.1001/jama.2013.905 – volume: 23 start-page: 439 issue: 3 year: 2018 end-page: 444 ident: CR16 article-title: Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus publication-title: Heart Fail Rev doi: 10.1007/s10741-018-9668-1 – volume: 143 start-page: 1673 year: 2021 end-page: 1686 ident: CR22 article-title: Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.052503 – volume: 142 start-page: 1028 issue: 11 year: 2020 end-page: 1039 ident: CR26 article-title: Empagliflozin in heart failure: diuretic and cardiorenal effects publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.045691 – volume: 23 start-page: 191 issue: 3 year: 2022 end-page: 197 ident: CR9 article-title: Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study publication-title: J Cardiovasc Med (Hagerstown) doi: 10.2459/JCM.0000000000001267 – volume: 117 start-page: 495 issue: 2 year: 2021 end-page: 507 ident: CR8 article-title: Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation publication-title: Cardiovasc Res doi: 10.1093/cvr/cvaa123 – volume: 7 start-page: 808 issue: 9 year: 2019 end-page: 817 ident: CR30 article-title: Diastolic determinants of excess mortality in heart failure with reduced ejection fraction publication-title: JACC Heart Fail doi: 10.1016/j.jchf.2019.04.024 – volume: 41 start-page: 255 issue: 2 year: 2020 end-page: 323 ident: CR1 article-title: 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD publication-title: Eur Heart J doi: 10.1093/eurheartj/ehz486 – volume: 373 start-page: 2117 issue: 22 year: 2015 end-page: 2128 ident: CR2 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1504720 – volume: 28 start-page: 1 issue: 1 year: 2015 end-page: 39e14 ident: CR11 article-title: Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging publication-title: J Am Soc Echocardiogr doi: 10.1016/j.echo.2014.10.003 – volume: 41 start-page: 3421 issue: 36 year: 2020 end-page: 3432 ident: CR15 article-title: A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial publication-title: Eur Heart J doi: 10.1093/eurheartj/ehaa419 – volume: 6 start-page: 836 issue: 7 year: 2021 end-page: 840 ident: CR19 article-title: Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2020.6827 – volume: 141 start-page: 704 issue: 8 year: 2020 end-page: 707 ident: CR27 article-title: Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.044235 – volume: 383 start-page: 1413 issue: 15 year: 2020 end-page: 1424 ident: CR4 article-title: Cardiovascular and renal outcomes with empagliflozin in heart failure publication-title: N Engl J Med doi: 10.1056/NEJMoa2022190 – volume: 20 start-page: 25 issue: 1 year: 2021 ident: CR12 article-title: Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-020-01209-y – volume: 77 start-page: 243 issue: 3 year: 2021 end-page: 255 ident: CR20 article-title: Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.11.008 – volume: 20 start-page: 1690 issue: 12 year: 2018 end-page: 1700 ident: CR7 article-title: Empagliflozin directly improves diastolic function in human heart failure publication-title: Eur J Heart Fail doi: 10.1002/ejhf.1328 – volume: 150 start-page: 604 issue: 9 year: 2009 end-page: 612 ident: CR10 article-title: A new equation to estimate glomerular filtration rate publication-title: Ann Intern Med doi: 10.7326/0003-4819-150-9-200905050-00006 – volume: 9 issue: 16 year: 2020 ident: CR17 article-title: Effect of luseogliflozin on heart failure with preserved ejection fraction in patients with diabetes mellitus publication-title: J Am Heart Assoc doi: 10.1161/JAHA.119.015103 – ident: CR5 – volume: 143 start-page: 510 issue: 5 year: 2021 end-page: 512 ident: CR14 article-title: Randomized, controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus: the IDDIA trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.051992 – volume: 36 issue: 8 year: 2020 ident: CR18 article-title: The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: the CANA-HF study publication-title: Diabetes Metab Res Rev doi: 10.1002/dmrr.3335 – volume: 6 start-page: 448 year: 2021 end-page: 456 ident: CR29 article-title: Association of global longitudinal strain with clinical status and mortality in patients with chronic heart failure publication-title: JAMA Cardiol. doi: 10.1001/jamacardio.2020.7184 – volume: 37 start-page: 1526 issue: 19 year: 2016 end-page: 1534 ident: CR3 article-title: Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv728 – volume: 385 start-page: 1451 issue: 16 year: 2021 end-page: 1461 ident: CR25 article-title: Empagliflozin in heart failure with a preserved ejection fraction publication-title: N Engl J Med doi: 10.1056/NEJMoa2107038 – volume: 59 start-page: 575 issue: 4 year: 2022 end-page: 578 ident: CR21 article-title: Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial publication-title: Acta Diabetol doi: 10.1007/s00592-021-01823-6 – volume: 32 start-page: 712 issue: 6 year: 2011 end-page: 720 ident: CR28 article-title: Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data publication-title: Eur Heart J doi: 10.1093/eurheartj/ehq473 – volume: 6 start-page: 836 issue: 7 year: 2021 ident: 2164_CR19 publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2020.6827 – volume: 142 start-page: 1028 issue: 11 year: 2020 ident: 2164_CR26 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.045691 – volume: 150 start-page: 604 issue: 9 year: 2009 ident: 2164_CR10 publication-title: Ann Intern Med doi: 10.7326/0003-4819-150-9-200905050-00006 – volume: 7 start-page: 808 issue: 9 year: 2019 ident: 2164_CR30 publication-title: JACC Heart Fail doi: 10.1016/j.jchf.2019.04.024 – volume: 61 start-page: 2108 issue: 10 year: 2018 ident: 2164_CR6 publication-title: Diabetologia doi: 10.1007/s00125-018-4670-7 – volume: 381 start-page: 1995 issue: 21 year: 2019 ident: 2164_CR13 publication-title: N Engl J Med doi: 10.1056/NEJMoa1911303 – volume: 309 start-page: 781 issue: 8 year: 2013 ident: 2164_CR23 publication-title: JAMA doi: 10.1001/jama.2013.905 – volume: 370 start-page: 1383 issue: 15 year: 2014 ident: 2164_CR24 publication-title: N Engl J Med doi: 10.1056/NEJMoa1313731 – volume: 117 start-page: 495 issue: 2 year: 2021 ident: 2164_CR8 publication-title: Cardiovasc Res doi: 10.1093/cvr/cvaa123 – volume: 28 start-page: 1 issue: 1 year: 2015 ident: 2164_CR11 publication-title: J Am Soc Echocardiogr doi: 10.1016/j.echo.2014.10.003 – volume: 59 start-page: 575 issue: 4 year: 2022 ident: 2164_CR21 publication-title: Acta Diabetol doi: 10.1007/s00592-021-01823-6 – volume: 41 start-page: 255 issue: 2 year: 2020 ident: 2164_CR1 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehz486 – volume: 20 start-page: 25 issue: 1 year: 2021 ident: 2164_CR12 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-020-01209-y – volume: 141 start-page: 704 issue: 8 year: 2020 ident: 2164_CR27 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.044235 – volume: 385 start-page: 1451 issue: 16 year: 2021 ident: 2164_CR25 publication-title: N Engl J Med doi: 10.1056/NEJMoa2107038 – volume: 383 start-page: 1413 issue: 15 year: 2020 ident: 2164_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa2022190 – volume: 20 start-page: 1690 issue: 12 year: 2018 ident: 2164_CR7 publication-title: Eur J Heart Fail doi: 10.1002/ejhf.1328 – volume: 37 start-page: 1526 issue: 19 year: 2016 ident: 2164_CR3 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv728 – volume: 143 start-page: 1673 year: 2021 ident: 2164_CR22 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.052503 – volume: 32 start-page: 712 issue: 6 year: 2011 ident: 2164_CR28 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehq473 – volume: 77 start-page: 243 issue: 3 year: 2021 ident: 2164_CR20 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.11.008 – volume: 41 start-page: 3421 issue: 36 year: 2020 ident: 2164_CR15 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehaa419 – volume: 23 start-page: 439 issue: 3 year: 2018 ident: 2164_CR16 publication-title: Heart Fail Rev doi: 10.1007/s10741-018-9668-1 – volume: 6 start-page: 448 year: 2021 ident: 2164_CR29 publication-title: JAMA Cardiol. doi: 10.1001/jamacardio.2020.7184 – volume: 36 issue: 8 year: 2020 ident: 2164_CR18 publication-title: Diabetes Metab Res Rev doi: 10.1002/dmrr.3335 – volume: 373 start-page: 2117 issue: 22 year: 2015 ident: 2164_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMoa1504720 – ident: 2164_CR5 doi: 10.1056/NEJMoa2107038 – volume: 9 issue: 16 year: 2020 ident: 2164_CR17 publication-title: J Am Heart Assoc doi: 10.1161/JAHA.119.015103 – volume: 143 start-page: 510 issue: 5 year: 2021 ident: 2164_CR14 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.051992 – volume: 23 start-page: 191 issue: 3 year: 2022 ident: 2164_CR9 publication-title: J Cardiovasc Med (Hagerstown) doi: 10.2459/JCM.0000000000001267 – volume: 37 start-page: 1526 issue: 19 year: 2016 ident: 2164_CR31 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv728 |
| SSID | ssj0051034 |
| Score | 2.4038277 |
| Snippet | Background
The sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and... The sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and heart failure.... BackgroundThe sodium-glucose co-transporter 2 inhibitor empagliflozin improves cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM) and... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 911 |
| SubjectTerms | Aged Antidiabetics Blood pressure Body weight Cardiology Congestive heart failure Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diastolic pressure Double-Blind Method Double-blind studies Ejection fraction Erythrocytes Female Glucose transporter Heart failure Heart Failure - complications Heart Failure - diagnosis Heart Failure - drug therapy Hematocrit Hemoglobin Humans Male Mathematical analysis Medicine Medicine & Public Health Middle Aged NCT NCT02932436 Original Paper Placebos Pressure effects Sodium-Glucose Transporter 2 Inhibitors - adverse effects Stroke Volume Subgroups Treatment Outcome Uric acid Ventricle Ventricular Function, Left |
| SummonAdditionalLinks | – databaseName: ProQuest Health & Medical Collection (NC LIVE) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ditQwFA66gngj_m91lSN45wa36V96JaK7LMJ65cLclaRJtdBp1m3Lwl75ED6Zj-CTeE4m7TIuLszAlGRowjnJ-c5PvjD2BoWMZjqvOaJliQ6K0lzJwvBYNPgR6kB7EteTL_nxafp5la1CwG0IZZXznug3auNqipG_o4wfYmO05u_PfnC6NYqyq-EKjdvsjqcuQ30uVovDRWRxPqssc6rukWk4NOOPztGhVMHRYuEXXQZ-sW2YrqHN60WT_2ROvUE6esDuByQJHzaif8hu2f4Ru3sScuWP2e8NMfEArgGLi_5b1zadu2x7cD10thmBSh19_E-dA6oJwsCurYEsHUkLsCdVG_nfo4NpmPB1VClGLe1ykGsAiuUCxXJBwBzLhTUxfY7T8OfnL_Topw4HQkdZAAEnoH00bt1eWrMPxk26s1wj3MUnXyKmHQ8V9J01cLj-1Crwt4s8YadHh18_HvNwgwOv0yIbeS4Meiwq01Y1ZS2k1DVCOl3KVOIEkjS1UhVJZtGrwiaLrqEt0ceJG9SeTKgkecp2etfbXQZG6FjhfiGUMKmSuUI1ssIWoj6Q1pRxxOJZfFUd6M3plo2uWoiZvcgrFHnlRV5dROzt8p-zDbnHjb33Zq2owkIfqiu1jNjrpRmXKOVdVG_dhH2KglBmmeIgn22UaHkdEeYlCCkjJrfUa-lA9N_bLX373dOAIzQsE8S_EdufNfFqXP-fxvObp_GC3RN-VVBF8h7bGc8n-xJx16hf-cX1F5veL4Q priority: 102 providerName: ProQuest |
| Title | Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial |
| URI | https://link.springer.com/article/10.1007/s00392-023-02164-w https://www.ncbi.nlm.nih.gov/pubmed/36763159 https://www.proquest.com/docview/2829576929 https://www.proquest.com/docview/2775623941 https://pubmed.ncbi.nlm.nih.gov/PMC10293456 |
| Volume | 112 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLZYJyFeuF8yRnWQeGOeFufmPK6lZQKtQohK5SmyEwci0mRqEk3qEz-CX8ZP4Jdw7FxQN0Ca1KiN7DS2fOzzHZ9zPhPyCgcZ1bQfU0TLHA0UIangQUJtluKHiRNpSFzPF_7Z0n238lZdUljVR7v3LkmzUg_JbjqNlFHUMXghyKeXe2Tfs3nIR2T_9O3n97N-BdYkccabzH0d1cPdLlnm7_-yq5CuoczrwZJXPKZGEc3vkWXfhTb-5NtxU8vjeHuF3fGmfbxP7nbIFE5bUXpAbqniIbl93vneH5GfLdFxBWUKCheRL3mW5uU2K6AsIFdpDTp00uwnig2g2CGszLMYtObUow9YU0cvmd91CU3V4Ot05JkuyYbEsAr03jDovWFg0O8Nw1ozh9ZN9ev7j42qmhwbolNjAAEsoL5NynW2VckRJGUjc0Uldh_vTMiZLGkXkZ-rBGbrN5kAc1rJY7Kczz5Nz2h3IgSN3cCrqc8StICEJ5VIw5hxLmOEiDLkLscOOK6ruAgcT6GVhkUKTU0Vos1kpyiNHhOO84SMirJQzwgkTNoC1x8mWOIK7gsUS8VUwOITrpLQtojdi0UUd3Tp-tSOPBqIns1gRThYkRms6NIir4dnLlqykP_WPuylLeoWjirSjm00ARG0WuTlUIxTXvtxRKHKBusEgUatoYuNfNoK5_A6TcDnIES1CN8R26GCphPfLSmyr4ZWHKFm6CCetshRL5x_2vXvbhzcrPpzcocZ-dYRz4dkVG8a9QJxXS3HZC9YBWOczPPJZDHuJjV-T2aLDx-xdOpPfwPkI07a |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF5VqQRcKv7rUmCQ4ERX1Bv_rA8IAU2V0iZCqJV6M2t7DZYcu8S2InriIXgOHoZH4EmY2diuQkVvlRIp1m7kXc3szLfzy9hzJDKqaS_miJYlXlBUxJX0E26LFD9C7UamiOtk6o1PnA-n7uka-9XlwlBYZScTjaBOyphs5K_I44fYGLX5m7NvnLpGkXe1a6GxZItD_X2BV7bq9cEe0veFEPuj4_dj3nYV4LHjuzX3RIIoWrmRVmkQCymjGGFGFEhH4lkfOo6Wyh-6GpE-Dmm8rugAcbed4o5cocgAiiJ_3aGM1gFbfzeafvzUyX4qT2f82NKjeCLptGk6JlmP0mAFRx2JX7yk8MWqKryEby-Haf7jqzUqcP8222ixK7xdMtsdtqaLu-zGpPXO32O_l6WQKyhT0ChmvuRZmpfnWQFlAblOa6DgSmNxVHNAxkTgmWcxkG4l_gCcSfFN5nddQlM1-DqKTaORrE8dq4Csx0DWYxDQWY9hRrVF66b68-PnXFdNjguh5BlAiAuokZNylp3rZAeSsolyzSME2PhkgtKikrcx-7lOYDTbyxSYfib32cm1UPcBGxRloTcZJCKyFUoooUTiKOkpZFwttC_iXamTwLaY3ZEvjNuC6tTXIw_7UtCG5CGSPDQkDxcWe9n_52xZTuTK2dsdV4StaKnCi4NgsWf9MAoF8vSoQpcNzvF9wrWBg4t8uGSi_nVUom-IINZicoW9-glUcHx1pMi-msLjCEaDISJui-10nHixrv9vY-vqbTxlN8fHk6Pw6GB6-IjdEuaEUDz0NhvU80Y_RtRXR0_aowbs83Wf7r_35G1l |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF5VRaq4IP4JFBgkOFGrycaJ1weEEGnUUlpxoFJuZm2viyXHLrGtiJ54CJ6Gx-AReBK-2diuQkVvlRIp1m7kXc3szDe_K8RLEBlqehw5QMsKBooOHa282BnIBB-p-6Ft4np0PN4_cT_MRrMN8autheG0ylYmWkEdFxH7yHc54gdsDG2-mzRpEZ8m07dn3xy-QYojre11GisWOTTflzDfyjcHE9D6lZTTvc_v953mhgEncr1R5YxlDEStR6HRiR9JpcIIkCP0latw7oeua5T2hiMD1I8hA9PF-MDggwS7G0nNzlCI_xuY0mfDz5t1xh43qrMRbTXmzCLlNgU7tmyPC2KlA22JL8wVZ7muFC8h3csJm_9Eba0ynN4WtxoUS-9WbHdHbJj8rtg6auL098TvVVPkkoqEDATOaZYmWXGe5lTklJmkIk6ztL5HvSCwKCBolkbEWpY5hTCTM53s76qguqzxOs5S45G0KyIrif3IxH5kktT6kWnOXUaruvzz4-fClHWGhXAZDQHsEnRzXMzTcxPvUFzUYWacEFAbTzY9LSycJns_MzHtzSepJnuzyX1xci20fSA28yI3jwTFMhxoyCqpZexqNdZgYSONJ6O-MrE_6IlBS74galqr8w0fWdA1hbYkD0DywJI8WPbE6-4_Z6vGIlfO3m65ImiETBlcHImeeNENQzxwzEfnpqgxx_MY4fouFvlwxUTd67hZ3xBwtifUGnt1E7j1-PpInn61LcgBS_0hsHdP7LSceLGu_2_j8dXbeC62cKaDjwfHh0_ETWkPCCdGb4vNalGbp4B_VfjMnjMSX677YP8Fjp1wLA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+empagliflozin+on+left+ventricular+diastolic+function+in+addition+to+usual+care+in+individuals+with+type+2+diabetes+mellitus-results+from+the+randomized%2C+double-blind%2C+placebo-controlled+EmDia+trial&rft.jtitle=Clinical+research+in+cardiology&rft.au=Prochaska%2C+J%C3%BCrgen+H&rft.au=J%C3%BCnger%2C+Claus&rft.au=Schulz%2C+Andreas&rft.au=Arnold%2C+Natalie&rft.date=2023-07-01&rft.issn=1861-0692&rft.eissn=1861-0692&rft.volume=112&rft.issue=7&rft.spage=911&rft_id=info:doi/10.1007%2Fs00392-023-02164-w&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1861-0684&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1861-0684&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1861-0684&client=summon |